Status and phase
Conditions
Treatments
About
The purpose of this study is to demonstrate the safety of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UCMSCs) administered intravenously in patients with acute pulmonary inflammation due to COVID-19 with moderately severe symptoms
Sex
Ages
Volunteers
Inclusion criteria
Provide written informed consent
Male or female subjects age > 18 years at the time of signing the Informed Consent Form.
COVID-19 positive according to diagnosis (evaluated by reverse transcription (RT)-polymerase chain reaction (PCR) test confirming infection with severe acute respiratory syndrome coronavirus and clinical management of COVID-19 criteria (refer to appendix B)
Individuals with moderate to severe COVID-19 symptoms.
Adequate venous access
For female patients only, willingness to use FDA-recommended birth control until 6 months post treatment.
Must agree to comply with all study requirements and be willing to complete all study visits.
Need in-patient admission
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal